Early trial tests 'Double Antibody' to fight lupus by targeting rogue immune cells
NCT ID NCT06400537
Summary
This early-stage study is testing a new drug called A-319 for people with active or treatment-resistant lupus (SLE). The drug is designed to guide the body's own T cells to find and destroy harmful B cells that drive the disease. Researchers will enroll about 25 participants to primarily check the drug's safety and how the body handles it, while also looking for early signs it might help control lupus symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanxi Bethune Hospital
RECRUITINGTaiyuan, Shanxi, 030032, China
Contact Email: •••••@•••••
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.